A randomized, controlled study to evaluate safety and effectiveness of sirolimus Drug-Eluting Stent (DES) Integrated Delivery System (IDS) and Rapid Exchange (RX) platforms

Trial Profile

A randomized, controlled study to evaluate safety and effectiveness of sirolimus Drug-Eluting Stent (DES) Integrated Delivery System (IDS) and Rapid Exchange (RX) platforms

Recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Jan 2018

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Ischaemic heart disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms OPTIMIZE
  • Sponsors Svelte Medical Systems
  • Most Recent Events

    • 12 Jan 2018 New trial record
    • 10 Jan 2018 According to a Svelte Medical Systems media release, the first patient has been enrolled and treated in this trial at The Christ Hospital, Lindner Research Center in Cincinnati, Ohio by J.D. Corl. Dean Kereiakes is a principal investigator of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top